A multiepitope peptide vaccine against HCV ...
Type de document :
Compte-rendu et recension critique d'ouvrage
PMID :
Titre :
A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice
Auteur(s) :
Dawood, Reham [Auteur correspondant]
Moustafa, Rehab [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Abdelhafez, Tawfeek [Auteur]
El-Shenawy, Reem [Auteur]
El-Abd, Yasmine [Auteur]
Bader El Din, Noha [Auteur]
Dubuisson, Jean [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Awady, Mostafa [Auteur]
Moustafa, Rehab [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Abdelhafez, Tawfeek [Auteur]
El-Shenawy, Reem [Auteur]
El-Abd, Yasmine [Auteur]
Bader El Din, Noha [Auteur]
Dubuisson, Jean [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Awady, Mostafa [Auteur]
Titre de la revue :
BMC Infectious Diseases
Pagination :
932
Éditeur :
BioMed Central
Date de publication :
2019-11-05
ISSN :
1471-2334
Mot(s)-clé(s) en anglais :
HCV
Vaccine
Humoral response
Cellular response
Vaccine
Humoral response
Cellular response
Discipline(s) HAL :
Sciences du Vivant [q-bio]/Microbiologie et Parasitologie/Virologie
Sciences du Vivant [q-bio]/Immunologie/Vaccinologie
Sciences du Vivant [q-bio]/Immunologie/Vaccinologie
Résumé en anglais : [en]
BACKGROUND:Although DAAs hold promise to significantly reduce rates of chronic HCV infections, its eradication still requires development of an effective vaccine. Prolonged T cell responses and cross neutralizing antibodies ...
Lire la suite >BACKGROUND:Although DAAs hold promise to significantly reduce rates of chronic HCV infections, its eradication still requires development of an effective vaccine. Prolonged T cell responses and cross neutralizing antibodies are ideal for vaccination against the infection. We aimed to design and synthesize a 6 multi epitope peptide vaccine candidate and provide evidence for production of extended cellular and neutralizing Abs in mice.METHODS:Six peptides derived from conserved epitopes in E1, E2 (n = 2),NS4B, NS5A and NS5B were designed, synthesized in a multiple antigenic peptide (MAP) form and administered w/o adjuvant to BALB/c mice as HCVp6-MAP at doses ranging from 800 ng to 16 μg. Humoral responses to structural epitopes were assayed by ELISA at different times after injection. ELISpot assay was used to evaluate IFN ɣ producing CD4+/ CD8+ T- lymphocytes at extended durations i.e. > 20 weeks. Viral neutralization by mice sera was tested for genotypes 2a (JFH1) and a chimeric 2a/4a virus (ED43/JFH1) in HCVcc culture.RESULTS:HCVp6-MAP confers potent viral neutralization and specific cellular responses at > 1600 ng/ animal for at least 20 weeks.CONCLUSION:We report on a promising anti HCV vaccine for future studies on permissive hosts and in clinical trials.Lire moins >
Lire la suite >BACKGROUND:Although DAAs hold promise to significantly reduce rates of chronic HCV infections, its eradication still requires development of an effective vaccine. Prolonged T cell responses and cross neutralizing antibodies are ideal for vaccination against the infection. We aimed to design and synthesize a 6 multi epitope peptide vaccine candidate and provide evidence for production of extended cellular and neutralizing Abs in mice.METHODS:Six peptides derived from conserved epitopes in E1, E2 (n = 2),NS4B, NS5A and NS5B were designed, synthesized in a multiple antigenic peptide (MAP) form and administered w/o adjuvant to BALB/c mice as HCVp6-MAP at doses ranging from 800 ng to 16 μg. Humoral responses to structural epitopes were assayed by ELISA at different times after injection. ELISpot assay was used to evaluate IFN ɣ producing CD4+/ CD8+ T- lymphocytes at extended durations i.e. > 20 weeks. Viral neutralization by mice sera was tested for genotypes 2a (JFH1) and a chimeric 2a/4a virus (ED43/JFH1) in HCVcc culture.RESULTS:HCVp6-MAP confers potent viral neutralization and specific cellular responses at > 1600 ng/ animal for at least 20 weeks.CONCLUSION:We report on a promising anti HCV vaccine for future studies on permissive hosts and in clinical trials.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Source :
Fichiers
- https://www.hal.inserm.fr/inserm-02438162/document
- Accès libre
- Accéder au document
- https://www.hal.inserm.fr/inserm-02438162/document
- Accès libre
- Accéder au document
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6833294/pdf
- Accès libre
- Accéder au document
- https://www.hal.inserm.fr/inserm-02438162/document
- Accès libre
- Accéder au document
- s12879-019-4571-5.pdf
- Accès libre
- Accéder au document
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- s12879-019-4571-5.pdf
- Accès libre
- Accéder au document